Clinical endpoints in oncology - a primer

xlomafota13 shared this article with you from Inoreader Clinical endpoints in oncology - a primer Via American Journal of Cancer Research Am J Cancer Res. 2021 Apr 15;11(4):1121-1131. eCollection 2021. ABSTRACT Clinical endpoints are essential for assessing the safety and efficacy of new cancer therapies. They are used by oncologists to help guide clinical decision making. While overall survival (OS) has frequently been regarded as the "gold standard" primary clinical endpoint, it's utility is constrained by several disadvantages. The time-consuming nature of trials using OS has led to a recent push to explore surrogate clinical endpoints and their potential to serve as primary clinical endpoints in lieu of OS. Additionally, it is becoming evident that other endpoints add valuable information about quality of life and treatment failure as their use is becoming increasingly prevalent in oncology clinical trials. Without a doubt, the use of clinical endpoints will continue to expand and evolve as new cancer therapies are developed and novel treatments, including immunother apy, draw interest. This review explores the roles of primary and surrogate clinical endpoints as well as the benefits and drawbacks of each specific endpoint. In addition, it directly compares the unique features of each suggesting some of the specific uses each one fulfills. PMID:33948349 | PMC:PMC8085844 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.